Keywords Prostate, cancer, magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), Gleason score

Size: px
Start display at page:

Download "Keywords Prostate, cancer, magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), Gleason score"

Transcription

1 Original Article The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer Acta Radiologica 2016, Vol. 57(1) ! The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / acr.sagepub.com Johannes Nowak 1,2, Uwe Malzahn 3, Alexander DJ Baur 2, Uta Reichelt 4, Tobias Franiel 2,5, Bernd Hamm 2 and Tahir Durmus 2 Abstract Background: The ability to non-invasively analyze tumor aggressiveness is an important predictor for individual treatment stratification and patient outcome in prostate cancer (PCA). Purpose: To evaluate: (i) whether apparent diffusion coefficient (ADC), the T2 signal intensity (SI), and a combination of both parameters allow for an improved discrimination of Gleason Score (GS) 7 (intermediate and high risk) and GS <7 (low risk) in PCA; and (ii) whether ADC may distinguish between 3 þ 4 and 4 þ 3 PCA (primary Gleason grades [pgg]). Material and Methods: Prostatectomy specimens of 66 patients (mean age, years; 104 PCA foci) with a preceding multiparametric 1.5 T endorectal coil magnetic resonance imaging (MRI) were included. ADC (b values ¼ 0, 100, 400, 800 s/mm 2 ), standardized T2 (T2s), and the ADC/T2s ratio were tested for correlation with GS applying multivariate analysis. ADC cutoff values were calculated for prediction of GS and pgg, and logarithm of the odds (LOGIT) was used to express the probability for GS and pgg. Diagnostic accuracy was assessed by ROC analysis. Results: We found an almost linear negative relationship of ADC for GS 7 (P ¼ 0.002). The effect of ADC for GS 7 (adjusted odds ratio ¼ 0.995) was almost identical for peripheral and transition zone PCA (P ¼ and P < 0.001, respectively). ADC showed an AUC of 78.9% for discrimination between GS <7 and GS 7. An ADC cutoff of < mm 2 /s indicated a GS 7 (90.5% sensitivity, 62.5% specificity). Within the group of GS ¼ 7PCA,an ADC > mm 2 /s indicated a pgg of 3 (AUC ¼ 69.6%). Conclusion: T2s and the ADC/T2s ratio do not provide additional information regarding prediction of GS. ADC values have a good discriminatory power to distinguish tumors with GS 7 fromgs<7 and to predict pgg in GS ¼ 7PCA. Keywords Prostate, cancer, magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), Gleason score Date received: 24 May 2014; accepted: 8 November 2014 Introduction Prostate cancer (PCA) is the most frequent cancer in men in the Western world (1). Biologic aggressiveness of PCA varies greatly and is a key predictor of outcome (2). Although intensive research efforts have been made, and suspicious lesions of the prostate can now be identified at early stages, we still lack the ability to predict tumor aggressiveness non-invasively (3,4). Thus, radical prostatectomy and radiotherapy is the only definite treatment option for the majority of 1 Department of Radiology, Universitätsklinikum Würzburg, Germany 2 Department of Radiology, Charité Universitätsmedizin Berlin, Germany 3 Institute for Clinical Epidemiology and Biometry, Universität Würzburg, Germany 4 Institute for Pathology, Vivantes Klinikum am Urban Dieffenbachstrasse, Berlin, Germany 5 Department of Radiology, Universitätsklinikum Jena, Germany Corresponding author: Tahir Durmus, Department of Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, Berlin, Germany. tahir.durmus@charite.de

2 108 Acta Radiologica 57(1) patients to date, although a benefit for all patients is currently under debate (5). Histopathologically, the Gleason grading correlates with patient outcome, with higher Gleason scores (GS) indicating more aggressive PCA (6,7). However, 28 47% of transrectal ultrasound (TRUS)-guided prostate biopsies do not detect a present PCA (false negatives), and up to one-third of patients were upgraded to higher GS from biopsy to prostatectomy specimen (4,8,9). Multiparametric magnetic resonance imaging (MRI) of the prostate has emerged as a promising diagnostic tool for both detecting and grading PCA (10,11). However, the majority of published studies analyze the diagnostic value of MRI in detecting PCA only (10,12,13). It has been shown that ADC values were negatively correlated with the postsurgical GS in PCA patients. The ADC was furthermore sufficient to predict the presence of low-grade and high-grade PCA in the peripheral zone (PZ) (14 16). Regarding T2- weighted (T2W) images, it has been demonstrated that PCA have lower T2 signal intensity (SI) than non-neoplastic tissue (11). In a pilot study, Wang et al. found lower T2 SI values at 1.5 T to be associated with higher GS, suggesting that T2W imaging might as well enable non-invasive assessment of PCA aggressiveness (17). Given that both ADC and T2W SI thus correlate independently with the GS in PCA, their combination might improve PCA grading with MRI. The first aim of this study was to test whether ADC, standardized T2W imaging (T2s) and the combination of ADC and T2W imaging (ADC/T2s ratio) allow a better discrimination between low-risk (GS < 7) and intermediate or high-risk (GS 7) tumors, using histopathology after prostatectomy as reference standard. Furthermore, GS ¼ 7 tumors comprise a very heterogenous group of PCA. While a primary Gleason grade (pgg) of 3 might be interpreted as intermediate risk, a pgg of 4 is associated with a higher clinical risk (18). We therefore intended to calculate ADC cutoff values in order to non-invasively differentiate 3 þ 4 from 4 þ 3 PCA. Material and Methods Patient characteristics This study was approved by the institutional ethical review board, and written consent was obtained from every participant. A collective of 69 consecutive patients with biopsy proven PCA underwent endorectal multiparametric MRI. MRI was performed at least 4 weeks after TRUS-guided biopsy. Patients had a mean age of years (range, years) and a mean PSA of 17.5 ng/ml (range, ng/ml). Only patients with whole-mount, step-sectioned pathological evaluation of prostatectomy specimens were included in this retrospective analysis. Thus, three patients (one patient with metastatic disease underwent only lymphadenectomy and systemic therapy, two patients decided for primary radiation therapy) were excluded. The final study population consisted of 66 patients. MRI protocol MRI was performed on a 1.5 T MR scanner (Siemens Avanto, Erlangen, Germany) using a combined endorectal-pelvic phased array coil (Medrad, Pittsburgh, PA, USA). The MRI standard protocol included T1- weighted (T1W) images of the pelvis and prostate and multiplanar T2W images of the prostate. All MR sequences were performed with a image matrix (section thickness, 3.0 mm; intersection gap, 0.6 mm; 100% phase oversampling). After axial, coronal, and sagittal localizer sequences were obtained, an angulated axial T2W turbo spin echo (TSE) sequence (TR/TE, 4850/85 ms; echo train length, 15; averages, three; field of view [FOV], mm), an angulated coronal T2W TSE sequence (TR/TE, 4000/95 ms; echo train length, 13; averages, three; FOV, mm), and an angulated axial T1W TSE sequence (TR/TE 691/12 ms; echo train length, three; averages, two; FOV, mm) were acquired. Diffusion-weighted imaging (DWI) was acquired with the same slice thickness, gap, and axial angulation as the T2W TSE using gradient pulses applied along three orthogonal directions (x-, y-, and z-axes; TR/TE, 3000/69; number of signals acquired, eight; FOV, mm; image matrix, ; section thickness, 3.6 mm) with four b values of 0, 100, 400, and 800 s/mm 2. ADC maps were then automatically generated on the basis of a voxelwise calculation. Histopathological evaluation and MR correlation After surgical resection, whole prostate specimens were marked with ink (anterior, posterior, left, right) and then step-sectioned from apex to base in five to eight axial slices. After preparation for pathologic analysis (embedding of microslices in paraffin and staining with hematoxylin and eosin, segmentation into quadrants), cancer foci were identified and assigned a GS according to the modified Gleason grading system by a fellow pathologist experienced in genitourinary histopathology (UR) (6). Cancer foci were then graphically transferred to a standardized map. Only tumor foci larger than 5 mm were included into the analysis. If tumor foci touched each other in the drawings, they were regarded as one tumor focus. The pathologist and a radiologist (TD) jointly matched cancer foci in

3 Nowak et al. 109 pathologic maps with the corresponding T2W images and ADC maps. When necessary, anatomic landmarks, such as prostate zones, prostatic urethra, ejaculatory ducts, urinary bladder, and seminal vesicle tissue in superior imaging sections for guidance in order to find the most closely corresponding MRI for PCA foci were used. Image analysis and data acquisition Based on the pathological maps, elliptical region of interests (ROI) were placed on cancerous regions for SI measurements in T2W imaging and in the corresponding ADC maps by two radiologists in consensus (JN and TD, with 2 and 5 years of experience, respectively). ROIs were placed into the visually darkest tumor area, in order to avoid tumor edges and areas possibly containing hemorrhage. In patients with multifocal disease, each PCA lesion was measured separately and included in the study. Cancer size was measured in T2W imaging with the largest apparent tumor diameter. Furthermore, ROIs were placed in histologically confirmed PCA-free PZ in T2W imaging and ADC maps as controls. For normalization to an internal control as suggested by Wang et al., an additional ROI was placed in the internal obturator muscle. T2W imaging SI values of tumors in PZ and TZ were then divided by obturator muscle SI values, resulting in standardized T2 SI values (T2s) (17). Statistical analysis Ninety-five of the 104 cancers (91.3%) were GS of 6 or 7. Therefore the score variable was dichotomized and a binary target variable (GS < 7 versus GS 7) was obtained. Accounting for multiple cancer foci, measurements on different foci for the same patient were treated as correlated observations within the overall dataset. Thus a binary logistic modelling with GEE (generalized estimation equations) and LOGIT as link function (with LOGIT referring to natural logarithm of odds; LOGIT ¼ ln (p/1 p) with p ¼ probability for GS 7) under the mixed linear model framework was performed. We adjusted for PSA values and tumor diameter as covariates to correct for confounding factors. P values (P < were regarded as statistically significant) refer to the Wald test for GEE regression parameters. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic accuracy and calculate ADC cutoff values for the target variables (GS < 7, GS 7). For this analysis only data corresponding to the tumor lesion with the highest GS were used. Cutoff values for ADC were calculated in order to distinguish 3 þ 4 from 4 þ 3 cancers in GS ¼ 7 PCA. Sensitivities and specificities were calculated. Statistical analysis was performed using IBM SPSS for Windows (Version 20.0; SPSS Inc., Chicago, IL, USA). Results A total of 81 cancers were assigned to the peripheral zone (PZ) of the prostate, whereas 23 cancers were localized in the transition zone (TZ). In total 104 cancers in 66 patients were analyzed (Table 1). With respect to histopathological grading, we found one tumor with a GS of 3 þ 2 ¼ 5, 38 tumors with 3 þ 3 ¼ 6, 40 tumors of 3 þ 4 ¼ 7 and 17 tumors with 4 þ 3 ¼ 7, five tumors with 4 þ 4 ¼ 8, and three tumors with 4 þ 5/5 þ 4 ¼ 9. Table 2 presents basic descriptive statistics for the MR signal intensities (ADC, T2s, ADC/T2s ratio; cancer-free T2s and ADC as controls) of all cancers stratified by GS. Representative T2 TSE images of PCA with their corresponding ADC maps are shown in Fig. 1. We found an almost linear relationship and highly significant (P ¼ 0.002) influence of ADC values on LOGIT (GS 7). This corresponds to a reduction of the odds by a factor of per one unit increase in ADC SI (10 3 mm 2 /s). Lower ADC values were thus strongly associated with higher tumor aggressiveness in this study (Tables 2 and 3). ROC analysis of 66 tumors for ADC as marker for GS 7 showed an AUC of 78.9%, indicating that ADC values are appropriate for discrimination between GS < 7 and GS 7in our patient population (Fig. 2a). The effect (adjusted odds ratio [OR] ¼ 0.995) of ADC on the LOGIT of GS 7 was almost identical for PZ and TZ cancers, with P values of and <0.001, respectively (Table 4). Thus, lower ADC values significantly correlate with higher GS in both PZ and TZ cancers. Analyzing our raw data, there was no linear relationship between T2s and LOGIT (GS 7). We Table 1. Distribution of tumors. Tumors/patient Total tumors (n) Frequency % PZ TZ , , , , ,8 6 0 Total Distribution of tumors demonstrating a single tumor focus in 39 patients and multifocal disease in 27 patients. PZ, peripheral zone; TZ, transition zone.

4 110 Acta Radiologica 57(1) Table 2. ADC and T2s values in PCA. Gleason 6 Gleason 3 þ 4 Gleason 4 þ 3 Gleason 7 Gleason 8 ADC TZ þ PZ ADC TZ * ADC PZ ADC PZ Ctr T2s TZ þ PZ T2s TZ * T2s PZ T2s PZ Ctr ADC/T2s TZ þ PZ ADC/T2s TZ * ADC/T2s PZ ADC/T2s PZ Ctr ADC values [10 3 mm 2 /s] and standardized T2 SI (T2s) given as means standard error. Prostate tumors are listed in GS category, controls are measured in cancer-free PZ. *n ¼ 1. Ctr, control; PZ, peripheral zone; SI, signal intensity; TZ, transition zone. (a) (c) (e) (g) (b) (d) (f) (h) Fig. 1. Axial T2 TSE with corresponding ADC Maps. (a, b) Patient with an anterior prostate cancer lesion (arrows) in the PZ with GS of 3 þ 3 ¼ 6 and T2s of 2.36 and an ADC value of (c, d) Patient with localized cancer focus in the left apex with a GS 3 þ 4 ¼ 7, T2s of 2.44 and an ADC of (e, f) Patient with a laterally localized tumor in the PZ with a GS 4 þ 3 ¼ 7 and a T2s of 3.92 and an ADC of (g, h) Large right-sided PCA focus with bulging and histologically confirmed extracapsular extension of GS 5 þ 4 ¼ 9; T2s of 4.64 and an ADC of subsequently categorized T2s values into quartiles. A borderline effect was seen for overall T2s SI and prediction of GS 7 (P ¼ 0.050), with very high T2s values (fourth quartile) indicating a significantly lower probability of cancers with GS 7 (P ¼ 0.009), compared to low T2s values (first quartile; generalized linear modeling, adjusted for categorized PSA and cancer diameter variables; Table 3). T2s values in PZ cancers (n ¼ 81) show a similar effect as compared to the overall calculation, with an even stronger impact of high T2s values (fourth quartile) on the probability for lower tumor aggressiveness. There was no monotone

5 Nowak et al. 111 relationship between T2s with LOGIT (GS 7) in our subsample of TZ cancers, not allowing for further statistical analysis. In order to evaluate independency and potential additive effects of ADC and T2s SI with PCA grading, a ratio of these parameters was tested. However, the ADC/T2s ratio only confirmed the result that was seen for ADC values alone, but no additional information could be identified regarding correlation with GS (P ¼ 0.155). ADC cutoff values were calculated for different criteria: (i) for maximum values of both sensitivity (90.5%) and specificity (62.5%), ADC values Table 3. Results of multivariate analysis for ADC, T2s, and ADC/T2s. P value Adjusted OR 95% CI ADC (0.992, 0.998) T2s T2s fourth quartile (0.028, 0.606) T2s third quartile (0.166, 2.430) T2s second quartile (0.159, 3.061) T2s first quartile 1 ADC/T2s (0.985, 1.002) Multivariate analysis (separate models for ADC, T2s, and ADC/T2s) shows the relation of tumor ADC and T2s with LOGIT (GS 7) in all lesions. Adjusted for covariates (tumor diameter, PSA values). CI, confidence interval. lower than mm 2 /s indicated a GS 7; (ii) for high sensitivity (95.2%) and specificity of 50%, the cutoff ADC value for GS 7 was mm 2 /s (Table 5). In our analysis an ADC of > mm 2 /s indicated rather a 3 þ 4 type Gleason grade with an AUC of 69.6%, corresponding Table 4. Results of multivariate analysis for ADC and T2s in lesions of the PZ and TZ. P value Adjusted OR 95% CI PZ tumors ADC (0.990, 0.999) T2s T2s fourth quartile (0.018, 0.573) T2s third quartile (0.175, 4.966) T2s second quartile (0.739, 2.744) T2s first quartile 1 TZ tumors ADC < (0.992, 0.998) T2s * Multivariate analysis (separate models for ADC, T2s) shows the relation of tumor ADC and T2s with LOGIT (GS 7) in tumors of the PZ and TZ. Adjusted for covariates (tumor diameter, PSA values). *No monotone relationship between T2s and LOGIT (GS 7) in our subsample of TZ cancers, not allowing for further statistical analysis. PZ, peripheral zone; TZ, transition zone; CI, confidence interval. Fig. 2. (a) ROC analysis for ADC and GS (AUC ¼ 0.79). (b) Subgroup analysis of tumors with GS ¼ 7. ADC values to distinguish 3 þ 4 and 4 þ 3 Gleason grades (AUC ¼ 0.70).

6 112 Acta Radiologica 57(1) Table 5. ADC cutoff values for differentiation of Gleason grades. to a sensitivity and specificity of 77.5% and 64.7%, respectively (Fig. 2b). Discussion Sensitivity Specificity Cutoff for GS 7 ADC * ADC y 0.5 Cutoff for Gleason 3 þ 4 ADC > * ADC cutoff values for differentiation of Gleason grades in prostate tumors. *Maximum sensitivity and specificity. ymaximum sensitivity. DWI and ADC are rapidly gaining importance as reliable non-invasive markers for assessing the treatment response in a large variety of cancers (19). DWI is sensitive to the Brownian motion (¼diffusion) of free water molecules. Studies have been published that propose a relationship between DWI (ADC) and PCA aggressiveness (GS) (11,14,20). Lower ADC values in our study were significantly associated with intermediate or high risk PCA (GS 7), which is basically consistent with earlier research work on this topic (14,15,21). T2W imaging can be seen as water imaging, with PCA showing a high cell density with comparatively low T2 SI due to a decreased amount of free water (22). Wang et al. showed a negative correlation of standardized T2 values with GS (17). In our study, we could not generally confirm this finding; only very high T2s values (fourth quartile of our collective) were indicative of PCA with lower GS, whereas no significant relationship was found for the remaining T2s values. This finding might in part explain the finding of Doo et al., that addition of ADC to T2W imaging improves the accuracy of detecting intermediate or high risk PCA (GS 7), but not of low risk PCA (12). We also tested whether the combination of ADC with T2W imaging provides additional information regarding discrimination of low-grade from combined intermediate and high-grade PCA, and our results show that a ratio of the two parameters has no additive effect regarding prediction of GS, compared to ADC values alone. More importantly, we show that the ADC value might be able to separate PCA with a GS of 7 into the subgroups of 3 þ 4 ¼ 7 and 4 þ 3 ¼ 7 cancers, with an ADC > mm 2 /s indicating presence of 3 þ 4 Gleason grades (77.5% sensitivity, 64.7% specificity). This is consistent with a recent study of Verma et al., who found that mean values of Gleason grade 3 þ 4 cancers were significantly different from those of the reference category of 4 þ 3 cancers (15). The finding that PCA with GS of 3 þ 3, 3 þ 4or4þ 3 might be distinguished by ADC values indicates a major role for MRI in re-evaluation of patients during active surveillance (3,4,18). This is of special interest since studies suggest that Gleason 3 þ 4 and 4 þ 3 PCA are heterogeneous in terms of cancer-specific mortality, reflecting the different biological aggressiveness of GS ¼ 7 cancers and thus a need for different treatment regimens (2,18). Some other publications used prostatectomy specimens as reference standard for histopathology when correlating ADC values with GS (14,15,20,21,23 25); this is important since GS determined by TRUS tend to underestimate tumor grades (4,26). Additionally, a number of studies were restricted to cancer foci in the PZ of the prostate (14,20,23,24). Taking into consideration that PCA is a multifocal disease with approximately 30% of PCA arising in the TZ, the inclusion of cancers of the central gland is essential for clinical practice (27). In two publications the number of TZ cancers was too low for detailed statistical analysis (21,25). Verma et al. included 47 patients with at least one cancer focus in the TZ (15). They found a negative correlation of ADC values with GS in the PZ, as did the other studies. To the best of our knowledge, only a few studies with histological correlation on prostatectomy (investigating the value of high b-values at 3 T) described the predictive value of ADC for PCA in the TZ, which is consistent with our results, obtained with a maximal b-value of 800 s/mm 2 (28). In the present study, we were able to demonstrate negative correlation of ADC with GS in both the PZ and TZ. This is a clinically very important finding and further supports the qualification of DWI as a criterion for patient stratification. Our study may be limited by its retrospective design. Since this study was not intended to investigate the primary detection rate of MRI but its grading ability, matching of imaging with prostatectomy specimen seemed to be best qualified for this aim. We identified cancerous lesions in MRI according to pathologic maps of patients with known PCA before therapy. Slice thickness of prostatectomy specimens was not identical to MRI, which might have led to inaccuracies in lesion matching. Lesions were matched on a subjective basis in consensus of the pathologist and radiologist to minimize these inaccuracies. However, a digitalized prostatectomy specimen preparation would have been another objective method to match pathology and imaging. A potential limitation of our study is that we did not perform correction for endorectal coil artifacts using analytic coil correction software or a phantom study in order to identify SI isosurfaces on T2W imaging. However, Wang et al. showed that correction

7 Nowak et al. 113 did not significantly affect the results of their study compared to uncorrected images (17). Another limitation of our study might be related to the distribution of GS in our subgroup of patients, with the majority of cancers (91.3%) being of low and intermediate risk (with GS of 6 or 7). To address this issue, we dichotomized the score variable, leading to a binary target variable (GS < 7 representing low-risk and GS 7 representing intermediate and high-risk cancers). Furthermore, we included both PZ and TZ cancers and used a multivariate statistical analysis acknowledging multifocal tumors as dependent variables. Finally, ADC values may vary between institutions due to a number of reasons such as the used MRI scanner, field strength, and b-values. Further studies are needed to confirm our results and evaluate possible additive effects of absolute T2 relaxation times to ADC. In conclusion, our study indicates that ADC, but not T2W imaging as suggested by Wang et al, is an important and accurate parameter that correlates with GS in PCA of the PZ and TZ, and might furthermore help to differentiate 3 þ 4 and 4 þ 3 tumors in PCA with GS ¼ 7. Thus, the ADC value might be considered when classifying PCA patients into different treatment groups (according to low-, intermediate-, and high-risk cancers). Conflict of interest The study was performed at the Department of Radiology of the Charite Universita tsmedizin Berlin (CUB), Germany. The authors had full control of all primary data and all authors have participated sufficiently in the preparation of this work. The material in this paper represents exclusively our own work unless cited otherwise. Although not for this study explicitly, the Department of Radiology, CUB received grants from a variety of organizations as listed in the conflict disclosure form of the Department Director (Prof. Hamm). The other authors do not have a potential conflict of interest to disclose. The paper has not been published previously and is not currently under consideration for publication elsewhere. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. References 1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, CA Cancer J Clin 2010;60: Wright JL, Salinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 þ 3 and Gleason 3 þ 4 tumors in a population based cohort. J Urol 2009;182: Bul M, Zhu X, Rannikko A, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 2012;62: Shapiro RH, Johnstone PA. Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance. Urology 2012;80: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367: Epstein JI. An update of the Gleason grading system. J Urol 2010;183: Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111: Bak JB, Landas SK, Haas GP. Characterization of prostate cancer missed by sextant biopsy. Clin Prostate Cancer 2003;2: Fink KG, Hutarew G, Esterbauer B, et al. Evaluation of transition zone and lateral sextant biopsies for prostate cancer detection after initial sextant biopsy. Urology 2003;61: Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection histopathologic correlation. Radiology 2010;255: Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008;28: Doo KW, Sung DJ, Park BJ, et al. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol 2012;22: Tan CH, Wei W, Johnson V, et al. Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. Am J Roentgenol 2012;199: Nagarajan R, Margolis D, Raman S, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol 2012;2012: Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. Am J Roentgenol 2011;196: desouza NM, Riches SF, Vanas NJ, et al. Diffusionweighted magnetic resonance imaging: a potential noninvasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008;63: Wang L, Mazaheri Y, Zhang J, et al. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology 2008;246: Rasiah KK, Stricker PD, Haynes AM, et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 2003;98: Harry VN, Semple SI, Parkin DE, et al. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010;11: Bittencourt LK, Barentsz JO, de Miranda LC, et al. Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than

8 114 Acta Radiologica 57(1) TRUS-guided biopsies in peripheral zone tumours. Eur Radiol 2012;22: Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011;259: Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009;44: Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259: Itou Y, Nakanishi K, Narumi Y, et al. Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 2011;33: Oto A, Yang C, Kayhan A, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. Am J Roentgenol 2011;197: Epstein JI, Feng Z, Trock BJ, et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012;61: Bouye S, Potiron E, Puech P, et al. Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. Prostate 2009;69: Kitajima K, Takahashi S, Ueno Y, et al. Do apparent diffusion coefficient (ADC) values obtained using high b- values with a 3-T MRI correlate better than a transrectal ultrasound (TRUS)-guided biopsy with true Gleason scores obtained from radical prostatectomy specimens for patients with prostate cancer? Eur J Radiol 2013;82:

The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71 (2), Page

The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71 (2), Page The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71 (2), Page 2490-2497 Role of ADC Map MR Imaging in Prediction of Local Aggressiveness of Prostate Cancer Asaad Gamal Asaad Sorial, Omar Farouk

More information

Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging

Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging Poster No.: C-1766 Congress: ECR 2015 Type: Authors: Keywords: DOI: Scientific Exhibit J. Bae, C. K. Kim, S.

More information

The diagnosis and localization of prostate cancer are based on a digital

The diagnosis and localization of prostate cancer are based on a digital Diagn Interv Radiol 2011; 17:130 134 Turkish Society of Radiology 2011 ABDOMINAL IMAGING ORIGINAL ARTICLE The value of diffusion-weighted MRI for prostate cancer detection and localization Ahmet Baki Yağcı,

More information

Diffusion Weighted Imaging in Prostate Cancer

Diffusion Weighted Imaging in Prostate Cancer Diffusion Weighted Imaging in Prostate Cancer Disclosure Information Vikas Kundra, M.D, Ph.D. No financial relationships to disclose. Education Goals and Objectives To describe the utility of diffusion-weighted

More information

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department

More information

MR-US Fusion Guided Biopsy: Is it fulfilling expectations?

MR-US Fusion Guided Biopsy: Is it fulfilling expectations? MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology

More information

PI-RADS classification: prognostic value for prostate cancer grading

PI-RADS classification: prognostic value for prostate cancer grading PI-RADS classification: prognostic value for prostate cancer grading Poster No.: C-1622 Congress: ECR 2014 Type: Scientific Exhibit Authors: I. Platzek, A. Borkowetz, T. Paulus, T. Brauer, M. Wirth, M.

More information

MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review

MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.

More information

Apparent Diffusion Coefficient for Prostate Cancer Imaging: Impact of b Values

Apparent Diffusion Coefficient for Prostate Cancer Imaging: Impact of b Values Genitourinary Imaging Original Research Peng et al. Impact of b Value on Apparent Diffusion Coefficient in Prostate Cancer Imaging Genitourinary Imaging Original Research Yahui Peng 1 Yulei Jiang 2 Tatjana

More information

Genitourinary Imaging Original Research

Genitourinary Imaging Original Research Genitourinary Imaging Original Research Downloaded from www.ajronline.org by 1.1.3.3 on /7/1 from IP address 1.1.3.3. Copyright ARRS. For personal use only; all rights reserved Park et al. ADC in Prostate

More information

The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination

The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination Poster No.: C-2317 Congress: ECR 2014 Type: Scientific Exhibit Authors:

More information

PROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging

PROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role

More information

Prostate MRI: Access to and Current Practice of Prostate MRI in the United States

Prostate MRI: Access to and Current Practice of Prostate MRI in the United States Prostate MRI: Access to and Current Practice of Prostate MRI in the United States James L. Leake, MS a, Rulon Hardman, MD a, Vijayanadh Ojili, MD a, Ian Thompson, MD b, Alampady Shanbhogue, MD a, Javier

More information

Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)

Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%) Prostate MRI John Bell, MD Introduction Prostate Cancer Screening Staging Anatomy Prostate MRI overview Functional MRI Multiparametric Approach Indications Example Cases Overview Introduction Prostate

More information

Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144

Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What

More information

D. J. Margolis 1, S. Natarajan 2, D. Kumar 3, M. Macairan 4, R. Narayanan 3, and L. Marks 4

D. J. Margolis 1, S. Natarajan 2, D. Kumar 3, M. Macairan 4, R. Narayanan 3, and L. Marks 4 Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the Prostate D. J. Margolis 1, S. Natarajan 2, D. Kumar 3, M. Macairan 4, R. Narayanan 3, and L. Marks 4 1 Dept. of Radiology, UCLA, Los

More information

Genitourinary Imaging Original Research

Genitourinary Imaging Original Research Genitourinary Imaging Original Research Woodfield et al. DWI of Prostate Cancer Genitourinary Imaging Original Research Courtney A. Woodfield 1,2 Glenn A. Tung 1,2 David J. Grand 1,2 John A. Pezzullo 1,2

More information

Can Diffusion-Weighted Magnetic Resonance Imaging Predict a High Gleason Score of Prostate Cancer?

Can Diffusion-Weighted Magnetic Resonance Imaging Predict a High Gleason Score of Prostate Cancer? www.kjurology.org http://dx.doi.org/.4/kju.3.54.4.34 Urological Oncology Can Diffusion-Weighted Magnetic Resonance Imaging Predict a High Gleason Score of Prostate Cancer? Katsumi Shigemura,, Nozomu Yamanaka,3,

More information

Stephen McManus, MD David Levi, MD

Stephen McManus, MD David Levi, MD Stephen McManus, MD David Levi, MD Prostate MRI Indications INITIAL DETECTION, STAGING, RECURRENT TUMOR LOCALIZATION, RADIATION THERAPY PLANNING INITIAL DETECTION Clinically suspected prostate cancer before

More information

Cancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:

Cancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject: Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained

More information

Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers

Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers M. Scott Lucia, MD Professor and Vice Chair of Anatomic Pathology Chief of Genitourinary and Renal Pathology Dept. of

More information

Detection of prostate cancer by MR-ultrasound fusion guided biopsy

Detection of prostate cancer by MR-ultrasound fusion guided biopsy Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.

More information

DTI fiber tracking at 3T MR using b-1000 value in the depiction of periprostatic nerve before and after nervesparing prostatectomy

DTI fiber tracking at 3T MR using b-1000 value in the depiction of periprostatic nerve before and after nervesparing prostatectomy DTI fiber tracking at 3T MR using b-1000 value in the depiction of periprostatic nerve before and after nervesparing prostatectomy Poster No.: C-2328 Congress: ECR 2012 Type: Scientific Paper Authors:

More information

Multiparametric MRI diagnostic value in a case of prostate cancer

Multiparametric MRI diagnostic value in a case of prostate cancer CASE REPORT J. Transl. Med. Res 2015;20(3):162-167 Multiparametric MRI diagnostic value in a case of prostate cancer Gelu Adrian Popa 1,4, Ioana Gabriela Lupescu 1,4, Emi M. Preda 1,4, Cristina Nicolae

More information

Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate Cancer: Optimal B Value at 3T

Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate Cancer: Optimal B Value at 3T Original Article http://dx.doi.org/10.3348/kjr.2013.14.1.61 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2013;14(1):61-69 Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate

More information

Aims and objectives. Methods and materials. Background

Aims and objectives. Methods and materials. Background Updated Prostate Imaging Reporting and Data System (PI-RADS) 2.0 versus 1.0: detection accuracy of prostate clinically significant and insignificant cancer Poster No.: C-1203 Congress: ECR 2016 Type: Scientific

More information

MOLECULAR MEDICINE REPORTS 9: , Provincial Hospital, Shandong University, Jinan , P.R. China

MOLECULAR MEDICINE REPORTS 9: , Provincial Hospital, Shandong University, Jinan , P.R. China MOLECULAR MEDICINE REPORTS 9: 1989-1997, 2014 Magnetic resonance imaging directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12 core transrectal ultrasound guided

More information

Research Article Correlation of Gleason Scores with Diffusion-Weighted Imaging Findings of Prostate Cancer

Research Article Correlation of Gleason Scores with Diffusion-Weighted Imaging Findings of Prostate Cancer Hindawi Publishing Corporation Advances in Urology Volume 2012, Article ID 374805, 5 pages doi:10.1155/2012/374805 Research Article Correlation of Gleason Scores with Diffusion-Weighted Imaging Findings

More information

OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER

OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER By Dr. John Feller, MD, Radiologist Desert Medical Imaging, Palm Springs, CA MRI is clinically accepted as the best imaging modality for displaying anatomical

More information

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed

More information

Utility of Prostate MRI. John R. Leyendecker, MD

Utility of Prostate MRI. John R. Leyendecker, MD Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;

More information

Essential Initial Activities and Clinical Outcomes

Essential Initial Activities and Clinical Outcomes Essential Initial Activities and Clinical Outcomes Crystal Farrell 1,2 & Sabrina L. Noyes 2, Joe Joslin 2, Manish Varma 2,3, Andrew Moriarity 2,3, Christopher Buchach 2,3, Leena Mammen 2,3, Brian R. Lane

More information

Prostate Cancer: Comparison of Tumor Visibility on Trace Diffusion- Weighted Images and the Apparent Diffusion Coefficient Map

Prostate Cancer: Comparison of Tumor Visibility on Trace Diffusion- Weighted Images and the Apparent Diffusion Coefficient Map Genitourinary Imaging Original Research Rosenkrantz et al. Tumor Visibility in Prostate Cancer Genitourinary Imaging Original Research Andrew B. Rosenkrantz 1 Xiangtian Kong 2 Benjamin E. Niver 1 Douglas

More information

Whole-tumor apparent diffusion coefficient measurements in nephroblastoma: Can it identify blastemal predominance? Abstract Purpose To explore the

Whole-tumor apparent diffusion coefficient measurements in nephroblastoma: Can it identify blastemal predominance? Abstract Purpose To explore the Whole-tumor apparent diffusion coefficient measurements in nephroblastoma: Can it identify blastemal predominance? Abstract Purpose To explore the potential relation between whole-tumor apparent diffusion

More information

The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA

The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound Seyed Saeid Dianat, MD, 1 H. Ballentine Carter, MD, 2 Edward M. Schaeffer, MD, 2 Ulrike

More information

Diffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence After Radical Prostatectomy: Initial Experience

Diffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence After Radical Prostatectomy: Initial Experience EUROPEAN UROLOGY 61 (2012) 616 620 available at www.sciencedirect.com journal homepage: www.europeanurology.com Case Study of the Month Diffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence

More information

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory

More information

Prostate MRI: Who needs it?

Prostate MRI: Who needs it? Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center

More information

Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer

Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas

More information

Current Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR

Current Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR BETH ISRAEL DEACONESS MEDICAL CENTER Prostate MR Neil M. Rofsky, MD Harvard Medical School Current Clinical Practice DIGITAL RECTAL EXAMINATION PSA ( ~ 20% False negative) BIOPSY (18-25% False negative)

More information

Supplemental Information

Supplemental Information Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu

More information

PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW

PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW KP Murphy, A Walsh, C Donagh, R Aljurayyan, AC Harris, SD Chang Department of Abdominal and GU Radiology, Vancouver General Hospital & University of British Columbia,

More information

Low-Risk Prostate Cancer: The Accuracy of Multiparametric MR Imaging for Detection 1

Low-Risk Prostate Cancer: The Accuracy of Multiparametric MR Imaging for Detection 1 Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Jin Young Kim, MD

More information

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging Whole Body MRI Prostate Cancer recurrence, progression and restaging Dr. Nina Tunariu Consultant Radiology Drug Development Unit and Prostate Targeted Therapies Group 12-13 Janeiro 2018 Evolving Treatment

More information

Genitourinary Imaging Original Research

Genitourinary Imaging Original Research Genitourinary Imaging Original Research Felker et al. PI-RADSv2 Category 3 TZ Lesions Genitourinary Imaging Original Research Ely R. Felker 1 Steven S. Raman 1 Daniel J. Margolis 2 David S. K. Lu 1 Nicholas

More information

Diffusion-Weighted Imaging of Prostate Cancer

Diffusion-Weighted Imaging of Prostate Cancer ORIGINAL ARTICLE Diffusion-Weighted Imaging of Prostate Cancer Ryota Shimofusa, MD,* Hajime Fujimoto, MD, Hajime Akamata, MD, Ken Motoori, MD,* Seiji Yamamoto, MD,* Takuya Ueda, MD,* and Hisao Ito, MD*

More information

Effects of Post Biopsy Digital Rectal Compression on Improving Prostate Cancer Staging Using Magnetic Resonance Imaging in Localized Prostate Cancer

Effects of Post Biopsy Digital Rectal Compression on Improving Prostate Cancer Staging Using Magnetic Resonance Imaging in Localized Prostate Cancer Original Article http://dx.doi.org/10.3349/ymj.2013.54.1.81 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 54(1):81-86, 2013 Effects of Post Biopsy Digital Rectal Compression on Improving Prostate Cancer

More information

Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software

Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software Julien Le Nobin*, Clément Orczyk*, Fang-Ming Deng, Jonathan Melamed,

More information

Dong Hoon Lee, Kyo Chul Koo, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong and Byung Ha Chung

Dong Hoon Lee, Kyo Chul Koo, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong and Byung Ha Chung Jpn J Clin Oncol 2013;43(5)553 558 doi:10.1093/jjco/hyt041 Advance Access Publication 11 April 2013 Low-risk Prostate Cancer Patients Without Visible Tumor (T1c) On Multiparametric MRI Could Qualify for

More information

The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy

The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Original Article World J Nephrol Urol. 2018;7(1):12-16 The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Ragheed Saoud a, Albert El-Haj

More information

Genitourinary Imaging Original Research

Genitourinary Imaging Original Research Genitourinary Imaging Original Research De Cobelli et al. Use of Apparent Diffusion Coefficient to Predict Prostate Cancer Grade Genitourinary Imaging Original Research Francesco De Cobelli 1 Silvia Ravelli

More information

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril

More information

Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer

Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer T2 Combined with DWI for Prostate Cancer Localization Genitourinary Imaging Original Research Masoom A. Haider 1 Theodorus H. van der Kwast 2,3 Jeff Tanguay 2 Andrew J. Evans 2 Ali-Tahir Hashmi 1 Gina

More information

Prostate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX

Prostate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX Prostate MRI: Not So Difficult Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX What is the biggest barrier to your practice incorporating prostate MRI? 1) I don t know how to read the cases 2) I don

More information

A Comparison of Different Imaging Techniques for Localisation of Cancers in the Prostate

A Comparison of Different Imaging Techniques for Localisation of Cancers in the Prostate Send Orders for Reprints to reprints@benthamscience.net The Open Prostate Cancer Journal, 2014, 7, 1-6 1 Open Access A Comparison of Different Imaging Techniques for Localisation of Cancers in the Prostate

More information

Prostate Cancer Local or distant recurrence?

Prostate Cancer Local or distant recurrence? Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative

More information

Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template

Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template Abstract #17-130 ACR Annual Meeting 2017 Presenting Author: Whitney

More information

Shayan Sirat Maheen Anwar, 1 Zahid Anwar Khan, 2 Rana Shoaib Hamid, 3 Fahd Haroon, 4 Raza Sayani, 1 Madiha Beg, 1 and Yasir Jamil Khattak 1

Shayan Sirat Maheen Anwar, 1 Zahid Anwar Khan, 2 Rana Shoaib Hamid, 3 Fahd Haroon, 4 Raza Sayani, 1 Madiha Beg, 1 and Yasir Jamil Khattak 1 ISRN Radiology, Article ID 263417, 7 pages http://dx.doi.org/10.1155/2014/263417 Research Article Assessment of Apparent Diffusion Coefficient Values as Predictor of Aggressiveness in Peripheral Zone Prostate

More information

Prostate Cancer MRI. Accurate Diagnosis and Treatment. PSA to Prostate MRI. for patients and curious doctors

Prostate Cancer MRI. Accurate Diagnosis and Treatment. PSA to Prostate MRI. for patients and curious doctors 6 Prostate Cancer MRI Accurate Diagnosis and Treatment PSA to Prostate MRI for patients and curious doctors Samuel Aronson, M.D. Vincent Pelsser, M.D. Franck Bladou, M.D. Armen Aprikian, M.D. & Marc Emberton,

More information

prostate cancer diagnosis and patient management

prostate cancer diagnosis and patient management Isabelle oulay-oletta, M Groupe hospitalier Paris Saint-Joseph (St. Joseph Hospital) in Paris, France Synthetic diffusion: a robust sequence for prostate cancer diagnosis and patient management Located

More information

Prostate Biopsy in 2017

Prostate Biopsy in 2017 Prostate Biopsy in 2017 Bob Djavan, MD, PhD Professor and Chairman, Department of Urology, Rudolfinerhaus Foundation Hospital,Vienna, Austria Director Vienna Urology foundation Board member Scientific

More information

In 2005, International Society of Urological Pathology

In 2005, International Society of Urological Pathology ORIGINAL ARTICLE Gleason Score 3+4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen Cheng Cheng Huang, MD,*

More information

Problems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.

Problems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence. Multi-parametric MR imaging in Problems: TRUS Bx Low Risk Prostate Cancer Important cancers are missed Jelle Barentsz Clinically insignificant cancers are identified by Prostate MR Center of Excellence

More information

Anatomic Imaging of Prostate Cancer

Anatomic Imaging of Prostate Cancer Masoom Haider, MD, FRCP(C) Professor of Radiology, University of Toronto Clinician Scientist, Ontario Institute of Cancer Research Senior Scientist, Sunnybrook Research Institute Chief, Dept of Medical

More information

Differentiation of Noncancerous Tissue and Cancer Lesions by Apparent Diffusion Coefficient Values in Transition and Peripheral Zones of the Prostate

Differentiation of Noncancerous Tissue and Cancer Lesions by Apparent Diffusion Coefficient Values in Transition and Peripheral Zones of the Prostate JOURNAL OF MAGNETIC RESONANCE IMAGING 21:258 262 (2005) Original Research Differentiation of Noncancerous Tissue and Cancer Lesions by Apparent Diffusion Coefficient Values in Transition and Peripheral

More information

Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer

Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer RadioGraphics 2018; 38:437 449 Pritesh Patel, MD Melvy S. Mathew, MD Igor Trilisky, MD Aytekin Oto, MD, MBA Jeffrey S. Klein,

More information

Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer

Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas

More information

10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION

10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa

More information

Genitourinary Imaging Original Research

Genitourinary Imaging Original Research Genitourinary Imaging Original Research Kitajima et al. MRI of Local Recurrence After Prostatectomy Genitourinary Imaging Original Research Kazuhiro Kitajima 1,2 Robert P. Hartman 1 Adam T. Froemming 1

More information

Additional value of Diffusion Weighted Imaging in the detection and treatment of prostate cancer

Additional value of Diffusion Weighted Imaging in the detection and treatment of prostate cancer Additional value of Diffusion Weighted Imaging in the detection and treatment of prostate cancer Poster No.: C-2000 Congress: ECR 2013 Type: Scientific Exhibit Authors: A. F. Syed abbas hasan, A. J. Clark,

More information

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,

More information

NIH Public Access Author Manuscript Abdom Imaging. Author manuscript; available in PMC 2015 October 01.

NIH Public Access Author Manuscript Abdom Imaging. Author manuscript; available in PMC 2015 October 01. NIH Public Access Author Manuscript Published in final edited form as: Abdom Imaging. 2014 October ; 39(5): 1027 1035. doi:10.1007/s00261-014-0136-7. Abnormal findings on multiparametric prostate magnetic

More information

Prostate biopsy: MR imaging to the rescue

Prostate biopsy: MR imaging to the rescue Prostate biopsy: MR imaging to the rescue Poster No.: C-1855 Congress: ECR 2014 Type: Educational Exhibit Authors: N. V. V. B. Marques 1, J. Ip 1, A. Loureiro 2, J. Niza 1, M. Palmeiro 2, Keywords: DOI:

More information

Mucinous Adenocarcinoma of the Prostate: MRI and MR Spectroscopy Features

Mucinous Adenocarcinoma of the Prostate: MRI and MR Spectroscopy Features Genitourinary Imaging Clinical Observations Westphalen et al. MRI of Mucinous Adenocarcinoma of the Prostate Genitourinary Imaging Clinical Observations Antonio C. Westphalen 1 Fergus V. Coakley 1 John

More information

بسم هللا الرحمن الرحيم. Prof soha Talaat

بسم هللا الرحمن الرحيم. Prof soha Talaat بسم هللا الرحمن الرحيم Ovarian tumors The leading indication for gynecologic surgery. Preoperative characterization of complex solid and cystic adnexal masses is crucial for informing patients about possible

More information

Magnetic Resonance Imaging Targeted Biopsy of the Prostate

Magnetic Resonance Imaging Targeted Biopsy of the Prostate Magnetic Resonance Imaging Targeted Biopsy of the Prostate Policy Number: 7.01.152 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis

Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis Genitourinary Imaging Original Research de Rooij et al. Multiparametric MRI for Prostate Cancer Detection Genitourinary Imaging Original Research Maarten de Rooij 1,2 Esther H. J. Hamoen 1,3 Jurgen J.

More information

Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Significance

Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Significance Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images Duc Fehr a,1, Harini Veeraraghavan a,1,2, Andreas Wibmer b, Tatsuo Gondo c, Kazuhiro Matsumoto

More information

Optimizing Implementation of Prostate MRI. Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department

Optimizing Implementation of Prostate MRI. Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department Optimizing Implementation of Prostate MRI Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department Objectives To review the basic components of a state-of-the-art mpmri of the

More information

Yahui Peng, PhD 2 Yulei Jiang, PhD Tatjana Antic, MD Maryellen L. Giger, PhD Scott E. Eggener, MD Aytekin Oto, MD. Purpose: Materials and Methods:

Yahui Peng, PhD 2 Yulei Jiang, PhD Tatjana Antic, MD Maryellen L. Giger, PhD Scott E. Eggener, MD Aytekin Oto, MD. Purpose: Materials and Methods: Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Validation of Quantitative

More information

PCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."

PCa Commentary. Executive Summary: The PCa risk increased directly with increasing phi values. 1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A

More information

PI-RADS version 2 - what we need to know

PI-RADS version 2 - what we need to know PI-RADS version 2 - what we need to know Poster No.: C-1846 Congress: ECR 2017 Type: Educational Exhibit Authors: I. Abreu, D. Roriz, A. P. Pissarra, Â. Moreira, C. B. Marques, 1 1 2 1 1 1 1 2 F. Caseiro

More information

MRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC

MRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC MRI Based treatment planning for with focus on prostate cancer Xinglei Shen, MD Department of Radiation Oncology KUMC Overview How magnetic resonance imaging works (very simple version) Indications for

More information

Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?

Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter? ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate

More information

Recently, prostate-specific antigen (PSA) has been identified as a

Recently, prostate-specific antigen (PSA) has been identified as a Diagn Interv Radiol 2011; 17:243 248 Turkish Society of Radiology 2011 ABDOMINAL IMAGING ORIGINAL ARTICLE Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition

More information

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation. Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product

More information

Detection, Screening and. Jelle Barentsz, Radboudumc, Nijmegen, NL

Detection, Screening and. Jelle Barentsz, Radboudumc, Nijmegen, NL Detection, Screening and Staging with mpmri Jelle Barentsz, Radboudumc, Nijmegen, NL NO CONFLICT OF INTEREST Paradigm shift Past staging TRUS-GBx ERC, MRSI invasive Current detection agressive PCa mpmri-directed

More information

Correlated diffusion imaging

Correlated diffusion imaging Wong et al. BMC Medical Imaging 2013, 13:26 RESEARCH ARTICLE Open Access Correlated diffusion imaging Alexander Wong 1*, Jeffrey Glaister 1,AndrewCameron 1 and Masoom Haider 2 Abstract Background: Prostate

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme

Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme Adil Bata 1, Jai Shankar 2 1 Faculty of Medicine, Class of 2017 2 Department of Diagnostic Radiology, Division of Neuroradiology,

More information

Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,

More information

Diffusion weighted MRI in evaluation of transplanted kidney: Preliminary clinical experience

Diffusion weighted MRI in evaluation of transplanted kidney: Preliminary clinical experience African Journal of Nephrology (2009) 13: 26-30 Original Article AJN Diffusion weighted MRI in evaluation of transplanted kidney: Preliminary clinical experience Mohamed Abou El-Ghar; M.D, Huda Refaie;

More information

High-Resolution Diffusion-Weighted Imaging of the Prostate

High-Resolution Diffusion-Weighted Imaging of the Prostate Genitourinary Imaging Original Research Medved et al. High-Resolution DWI of the Prostate Genitourinary Imaging Original Research Milica Medved 1 Fatma N. Soylu-oy 1,2 Ibrahim Karademir 1,3 Ila Sethi 1,4

More information

MR cholangiopancreatography; Predicting imaging findings for differentiation of malignant bile ductal obstruction versus benign lesion

MR cholangiopancreatography; Predicting imaging findings for differentiation of malignant bile ductal obstruction versus benign lesion Acta Med Kindai Univ Vol.43, No.1 1-8, 2018 1 MR cholangiopancreatography; Predicting imaging findings for differentiation of malignant bile ductal obstruction versus benign lesion Shojiro Hidaka 1,2,

More information

FieldStrength. Multi-parametric 3.0T MRI provides excellent prostate imaging

FieldStrength. Multi-parametric 3.0T MRI provides excellent prostate imaging FieldStrength Publication for the Philips MRI Community Issue 35 September / October 2008 Multi-parametric 3.0T MRI provides excellent prostate imaging Three different centers show that advances in imaging

More information

Standards for MRI reporting the evolution to PI-RADS v 2.0

Standards for MRI reporting the evolution to PI-RADS v 2.0 Review Article Standards for MRI reporting the evolution to PI-RADS v 2.0 Michael Spektor, Mahan Mathur, Jeffrey C. Weinreb Department of Radiology and Biomedical Imaging, Yale New Haven Hospital, USA

More information

MR IMAGING OF THE PROSTATE AT 3.0T WITH EXTERNAL PHASED ARRAY COIL PRELIMINARY RESULTS

MR IMAGING OF THE PROSTATE AT 3.0T WITH EXTERNAL PHASED ARRAY COIL PRELIMINARY RESULTS EUROPEAN JOURNAL OF MEDICAL RESEARCH 287 Eur J Med Res (2008) 13: 287-291 I. Holzapfel Publishers 2008 MR IMAGING OF THE PROSTATE AT 3.0T WITH EXTERNAL PHASED ARRAY COIL PRELIMINARY RESULTS N. Morakkabati-Spitz

More information

Advances in Magnetic Resonance Imaging: How They Are Changing the Management of Prostate Cancer

Advances in Magnetic Resonance Imaging: How They Are Changing the Management of Prostate Cancer EUROPEAN UROLOGY 59 (2011) 962 977 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Prostate Cancer Advances in Magnetic Resonance Imaging: How They Are Changing the

More information

Abdominal applications of DWI

Abdominal applications of DWI Postgraduate course, SPR San Antonio (Texas), May 14-15, 2013 Abdominal applications of DWI Rutger A.J. Nievelstein Wilhelmina Children s s Hospital, Utrecht (NL) Outline What is DWI? How to perform? Challenges

More information

Magnetic resonance imaging predictors of extracapsular extension of prostate cancer: Do they accurately reflect pt3 staging?

Magnetic resonance imaging predictors of extracapsular extension of prostate cancer: Do they accurately reflect pt3 staging? Magnetic resonance imaging predictors of extracapsular extension of prostate cancer: Do they accurately reflect pt3 staging? Poster No.: C-1399 Congress: ECR 2010 Type: Scientific Exhibit Topic: Genitourinary

More information